LGVN 📈 Longeveron - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US54303L1044
LGVN: Aging, Cellular, Therapies, Stem, Cells, Biotechnology, Medicines
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida. Web URL: https://longeveron.com
Additional Sources for LGVN Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
LGVN Stock Overview
| Market Cap in USD | 28m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2021-02-12 |
LGVN Stock Ratings
| Growth 5y | -85.3% |
| Fundamental | -72.2% |
| Dividend | - |
| Rel. Strength Industry | -6820 |
| Analysts | 4/5 |
| Fair Price Momentum | 1.10 USD |
| Fair Price DCF | - |
LGVN Dividends
No Dividends PaidLGVN Growth Ratios
| Growth Correlation 3m | -56.8% |
| Growth Correlation 12m | -49.1% |
| Growth Correlation 5y | -88.9% |
| CAGR 5y | -61.28% |
| CAGR/Mean DD 5y | -0.77 |
| Sharpe Ratio 12m | -0.24 |
| Alpha | -116.52 |
| Beta | 1.26 |
| Volatility | 106.04% |
| Current Volume | 284.2k |
| Average Volume 20d | 325.6k |
What is the price of LGVN stocks?
As of January 10, 2025, the stock is trading at USD 1.81 with a total of 284,188 shares traded.
Over the past week, the price has changed by +1.12%, over one month by -12.56%, over three months by -1.63% and over the past year by -85.63%.
As of January 10, 2025, the stock is trading at USD 1.81 with a total of 284,188 shares traded.
Over the past week, the price has changed by +1.12%, over one month by -12.56%, over three months by -1.63% and over the past year by -85.63%.
Is Longeveron a good stock to buy?
No, based on ValueRay Fundamental Analyses, Longeveron (NASDAQ:LGVN) is currently (January 2025) a stock to sell. It has a ValueRay Fundamental Rating of -72.18 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of LGVN as of January 2025 is 1.10. This means that LGVN is currently overvalued and has a potential downside of -39.23%.
No, based on ValueRay Fundamental Analyses, Longeveron (NASDAQ:LGVN) is currently (January 2025) a stock to sell. It has a ValueRay Fundamental Rating of -72.18 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of LGVN as of January 2025 is 1.10. This means that LGVN is currently overvalued and has a potential downside of -39.23%.
Is LGVN a buy, sell or hold?
Longeveron has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy LGVN.
Longeveron has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy LGVN.
- Strong Buy: 0
- Buy: 3
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecast for LGVN stock price target?
According to ValueRays Forecast Model, LGVN Longeveron will be worth about 1.2 in January 2026. The stock is currently trading at 1.81. This means that the stock has a potential downside of -32.04%.
According to ValueRays Forecast Model, LGVN Longeveron will be worth about 1.2 in January 2026. The stock is currently trading at 1.81. This means that the stock has a potential downside of -32.04%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 8.9 | 390.6% |
| Analysts Target Price | 8.9 | 390.6% |
| ValueRay Target Price | 1.2 | -32% |